{"page_content": "2020 CORPORATE SOCIAL RESPONSIBILITY REPORT32\nDear Communities\nABOUT SERVE TRANSFORM ADVANCE REDEFINE ETHICS & COMPLIANCE REPORTING INDEX   \n Matt:  \nIncredible work, \nMoke. Our Global  \nAccess to Medicines  \n(GATM) program has \nmade great strides \nthis year, too \u2013 and I\u2019m \nexcited to be part of \nthe team that\u2019s driving \nthis. GATM enables \neligible patients to \nreceive our therapies \nwhile we work toward \nthe development of \nlong-term commercial access solutions in the \ngeographies in which \nAlexion has sustainable \noperations around \nthe globe. Among \nthe most important \nadvancements to  \nGATM in 2020 is the \nability for patients \nwho have successfully \ncompleted an Alexion \nPhase III clinical trial to \ncontinue the treatment \nuntil they can receive \nother alternative  \nmeans of access.\nIn the U.S., the Alexion \nAccess Foundation \n(AAF) enables certain \npatients who have \nbeen diagnosed with \na disease for which \nAlexion has an FDA-\napproved medicine to \ngain access without \nMatt Staffier,\nExecutive Director of \nMedical Operations\nMoke Sharma, \nHead of Development Operations \nand Quantitative SciencesMAKING SIGNIFICANT STRIDES IN  \nACCESS TO MEDICINES\n Matt:   \nAt Alexion, we \nrecognize that access \nto medicine can be \nchallenging, and we \nare committed to \nproviding patients \nwith rare diseases and \ndevastating conditions \naccess to our therapies \nin the absence of \nalternatives. \n Moke:   \nThat\u2019s exactly \nright, Matt. That\u2019s \nwhy in 2020, we \nintroduced Expanded  \nAccess Programs  \n(EAP) at Alexion to \nprovide pathways for \npatients suffering from \na serious condition \nto gain access to \ninvestigational \nmedicines outside  \nof clinical trials. insurance, access to \ninsurance or any other \nmeans of obtaining \nAlexion medication. \n Moke:   \nThese programs \nand more speak to \nAlexion\u2019s commitment \nPROVIDING MORE   \nOPTIONS FOR PATIENTS  \nPart of understanding the patient journey is \nproviding more options for patients and making \nit easier for patients to access our medicines. \nThat is the inspiration behind our testing an \nULTOMIRIS\u00ae (ravulizumab-cwvz) subcutaneous \nformulation and device combination for PNH \nand aHUS that can be self-administered at \nhome. We plan to submit regulatory filings  \nin the U.S. and EU in the third quarter of 2021, \npending completion of the ongoing Phase III \nstudy and collection of 12-month safety data.to support patients \nwith the right \ntreatment.\nSincerely,\nMatt  \nand Moke\nMoke, working at  \nhis home office", "metadata": {"source": "NASDAQ_ALXN_2020.pdf", "page": 31, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}